珠海都市网
您当前的位置 :首页 > 文传商讯 > 正文
Landmark EMPA-KIDNEY trial showed significant benefit of Jardiance in reducing kidney disease progression or cardiovascular death by 28% vs. placebo in people with chronic kidney disease
2022年11月10日 13:59:12来源:作者:

- EMPA-KIDNEY, the largest and broadest dedicated SGLT2 inhibitor trial in chronic kidney disease, provides new evidence for patients commonly seen in clinical practice1,2

- Phase III trial also demonstrated a statistically significant reduction (14%) in hospitalization for any cause,1,2 bringing potential relief for patients and reducing burden on healthcare systems3

OXFORD, England & INGELHEIM, Germany & RIDGEFIELD, Conn. & INDIANAPOLIS, Ind.--(BUSINESS WIRE)--EMPA-KIDNEY Phase III clinical trial met its primary endpoint by demonstrating a significant kidney and cardiovascular benefit for adults living with chronic kidney disease (CKD).1,2 When treated with empagliflozin, the risk of kidney disease progression or cardiovascular death was significantly reduced by 28% vs. placebo (HR; 0.72; 95% CI 0.64 to 0.82; P<0.000001).1,2 The results were announced today during the American Society of Nephrology (ASN)’s Kidney Week 2022 by the Medical Research Council Population Health Research Unit (MRC PHRU) at the University of Oxford which designed, conducted and analyzed EMPA-KIDNEY, in a scientific collaboration with Boehringer Ingelheim, and Eli Lilly and Company (NYSE: LLY). The results were also published simultaneously in The New England Journal of Medicine.2

EMPA-KIDNEY is the first SGLT2 inhibitor CKD trial to demonstrate a significant reduction in all-cause hospitalizations (14%) (HR; 0.86; 95% CI 0.78 to 0.95; p=0.0025) vs. placebo, one of the pre-specified key secondary confirmatory endpoints.1,2 CKD doubles a person’s risk for hospitalization and is a leading cause of death globally.4,5 Hospitalizations account for 35%-55% of total healthcare costs for people with CKD in the U.S.6

The overall safety data was generally consistent with previous findings, confirming the well-established safety profile of empagliflozin.

“We know that there is an urgent need for new therapies proven to delay CKD progression which can lead to the need for dialysis or transplantation. Today’s results demonstrate that empagliflozin may benefit adults at risk of progression, including those with or without diabetes, and across a wide range of kidney function,” said William Herrington, Associate Professor at MRC PHRU (part of Oxford Population Health), and Honorary Consultant Nephrologist, and EMPA-KIDNEY co-Principal Investigator. “By reducing the risk of kidney disease progression or cardiovascular death, empagliflozin has the potential to positively impact healthcare systems worldwide.”

“The design of the EMPA-KIDNEY trial included a wider range of patients than ever before,” said Professor Richard Haynes, co-Principal Investigator. “Previous SGLT2 inhibitor trials focused on certain groups of people living with CKD, such as those with diabetes or high levels of protein in their urine. Today’s positive trial results across a broad CKD population reflect an opportunity to improve the treatment of this disease and prevent people from needing dialysis.”

EMPA-KIDNEY is the largest and broadest dedicated SGLT2 inhibitor trial to date.7 It included 6,609 participants across a wide range of underlying causes, many with co-morbidities across the spectrum of cardiovascular, kidney, or metabolic conditions. The trial assessed both kidney and cardiovascular outcomes in people across the spectrum of CKD severity.8

"The Boehringer Ingelheim and Lilly Alliance is incredibly proud that EMPA-KIDNEY has provided another pivotal moment for Jardiance,” said Carinne Brouillon, Head of Human Pharma and Member of the Board of Managing Directors, Boehringer Ingelheim. “Today’s data adds to the body of evidence from our clinical program which includes more than 700,000 adults with cardiovascular, kidney and metabolic conditions. EMPA-KIDNEY reinforces the potential role of empagliflozin in changing the way these interconnected conditions may be managed.”

Reductions in other key secondary endpoints of hospitalization for heart failure or cardiovascular death or all-cause death were not statistically significant, however the power to detect this was limited by the number of events observed. Reduction in the risk of these endpoints is consistent with the totality of the evidence from other trials which have shown statistical significance of these outcomes.

“Today’s EMPA-KIDNEY trial results will be welcomed by people living with CKD and the medical community. We are also encouraged by the risk reduction for hospitalization after just two years, as this finding is in line with the significant reductions seen in prior Jardiance cardiovascular outcomes trials,” says Jeff Emmick, M.D., Ph.D., Vice President, Product Development, Lilly. “The Alliance looks forward to discussing plans for marketing authorization for CKD with regulators worldwide in due course.”

Notes to editors

Kidney disease progression: Defined as end-stage kidney disease (the initiation of maintenance dialysis or receipt of a kidney transplant), a sustained decline in estimated glomerular filtration rate (eGFR) to below 10 mL/min/1.73 m2, kidney death or a sustained decline of at least 40 percent in eGFR from randomization).

End stage kidney disease: Includes initiation of maintenance dialysis or receipt of a kidney transplant

For further information on chronic kidney disease or cardio-renal-metabolic conditions, visit: www.boehringer-ingelheim.com/chronic-kidney-disease

Please click on the below link for further ‘Notes to editors’ and ‘References’:

https://www.boehringer-ingelheim.com/human-health/metabolic-diseases/full-data-chronic-kidney-disease-trial-efficacy

责任编辑: admin

看新闻,关注新闻

网易网友:心不亡wenod∕
评论:为何现在的女人上面穿羽绒服下面却穿丝袜.""问得好!因为鲜奶要保温、火腿要冷藏

凤凰网友:美丽/mmmmm
评论:爷爷说他们那个年代。谁考试不会答。就答说毛主席万岁。没人敢打叉。

天猫网友:他就是我的天
评论:令我感到骄傲和自豪的是,至今为止,地球仍被我踩在脚下。

腾讯网友:身軆被我所用
评论:领“鲜”一步

猫扑网友:厮守°- Michae
评论:我以前对你掏心掏肺 你却对我狼心狗肺 搞得我现在没心没肺

本网网友:Cold-blooded 凉薄
评论:我活这么大,拿得起放的下的东西只有筷子

百度网友:人身尽情挥霍
评论:我以为你牵我的左手会和我一起走,而你只是用我的衣服来擦手

天涯网友:关于病态美beauty ×
评论:下辈子做只考拉,每天睡觉20个小时,吃2个小时,发呆2 个小时,这就是完美人生啊。

搜狐网友:紅塵悲歡惆悵
评论:挣钱是一种能力,花钱是一种技术,我能力有限,技术却很高。

其它网友:失控-  Tender
评论:别把姐当备胎,姐是你换不起的轮子

相关阅读
分享到:
版权和免责申明

珠海都市网所有文字、图片、视频、音频等资料均来自互联网,不代表本站赞同其观点,本站亦不为其版权负责。相关作品的原创性、文中陈述文字以及内容数据庞杂本站无法一一核实,如果您发现本网站上有侵犯您的合法权益的内容,请联系我们,本网站将立即予以删除!